Neffy Adrenaline Nasal Spray
[vc_row][vc_column][vc_column_text css=""]
Nasal Adrenaline (neffy®) in Australia: What Educators Need to Know
With Neffy (nasal adrenaline) now available in Australia, questions will soon start coming up in education and training spaces.
While the delivery method is different, the principles of anaphylaxis management have not changed.
Neffy offers another way to administer adrenaline in an emergency. It doesn’t replace existing devices, and it doesn’t change how we recognise or respond to anaphylaxis. For educators, trainers and RTOs, the focus remains the same: clear teaching, consistent messaging, and supporting confidence in emergency decision-making.
What the evidence tells us
Guidance from ASCIA and the Australian Product Information confirms that:
-
Neffy is an approved nasal adrenaline option for the treatment of anaphylaxis
-
It does not replace adrenaline auto-injectors such as EpiPen; it is an alternative device
-
Emergency escalation remains mandatory: call 000 every time
-
If symptoms persist or worsen, a second dose may be given after 5 minutes
ASCIA continues to be the benchmark for evidence-based anaphylaxis management in Australia. Their device instructions are available here:
ASCIA How to Use Adrenaline Devices (2026):
https://www.allergy.org.au/images/stories/anaphylaxis/2025/ASCIA_How_to_use_adrenaline_devices_2026_4_red.pdf
Allergy & Anaphylaxis Australia have also provided a great overview of Neffy:
https://allergyfacts.org.au/neffy/
Details to highlight in training
While the core principles haven’t changed, there are some practical points that can make a real difference in correct use under pressure.
From a training perspective, it’s helpful to highlight that:
-
The device should not be test-sprayed. Each device contains a single dose
-
The nozzle is inserted straight into the nostril, directed towards the forehead
-
It should not be angled towards the septum or the outer wall of the nose
-
Firm activation is required
-
There is no need to sniff
-
If there is no improvement after 5 minutes, a second dose may be given using a new device
These are small details, but they matter. In an emergency, clarity and familiarity support confidence and reduce hesitation.
When teaching Neffy, it can be useful to spend time on positioning and activation techniques. Nasal delivery is mechanically different to auto-injectors, and learners benefit from clear demonstration and repetition, just as they do with injectable devices.
A manufacturer demonstration video is available here and can be a helpful supplementary resource alongside ASCIA guidance:
Neffy how-to video:
What hasn’t changed
It’s just as important to reinforce what remains the same:
-
Early recognition of anaphylaxis is critical
-
Adrenaline remains the first-line treatment
-
Emergency medical services must be contacted immediately
-
Ongoing monitoring is essential
The introduction of a nasal option shouldn’t create device comparison anxiety or hesitation in learners. Instead, it’s best positioned as an additional delivery option within established best practice.
Consistent language and messaging across training environments help reduce confusion and support confident responses.
Continuing Professional Development
Neffy, along with broader anaphylaxis management and teaching considerations, will be explored further at the upcoming Online CPR Kids Professional Development Day on 20 March 2026.
The session will focus on practical teaching considerations and updates.
NIFAT members are eligible for discounted registration.
[/vc_column_text][/vc_column][/vc_row]
Has anyone heard if there will be training devices available. No, I won't be getting people to put it up their nose, I mean in the touch and hake use like we have with Epi and Ana pens. Please let me know if you hear anything.